DUBLIN–(BUSINESS WIRE)–Sep 23, 2020–
Hidradenitis Suppurativa (HS)-Market Insights, Epidemiology and Market Forecast-2030′ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Hidradenitis Suppurativa Diagnosis
The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists, and biopsy is rarely required, especially in well-developed lesions. Primary Diagnosis of HS involves identification of the disease and assessment of its comorbidities. Fulfillment of three criteria are necessary for the diagnosis of HS:
- Typical lesions: deep-seated, painful nodules
- Characteristic distribution: Typical anatomical predilection (i.e., axillae, groins, perineal and perianal regions, buttocks, infra-mammary and inter-mammary folds)
Hidradenitis Suppurativa Treatment
It covers the details of conventional and current medical therapies available in the Hidradenitis Suppurativa market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.
The Hidradenitis Suppurativa market report gives a thorough understanding of Hidradenitis Suppurativa by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Hidradenitis Suppurativa treatment algorithms and treatment guidelines for Hidradenitis Suppurativa in the US, Europe, and Japan.
The total diagnosed incident cases of Hidradenitis Suppurativa (HS) patients were found to be more in females than in males in 7MM during the study period i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.
Country Wise- Hidradenitis Suppurativa Epidemiology
The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom) and Japan.
Hidradenitis Suppurativa Market Outlook
The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Hidradenitis Suppurativa market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017-2030.
- The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hidradenitis Suppurativa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hidradenitis Suppurativa market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hidradenitis Suppurativa market
1. Executive Summary: Hidradenitis Suppurativa (HS)
2. SWOT Analysis: Hidradenitis Suppurativa (HS)
3. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance
3.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030
4. Hidradenitis Suppurativa Market Overview at a Glance
4.1. Market Share (%) Distribution of Hidradenitis Suppurativa in 2017
4.2. Market Share (%) Distribution of Hidradenitis Suppurativa in 2030
5. Disease Overview: Hidradenitis Suppurativa (HS)
5.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)
5.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)
5.3.1. Hurley Stages of HS
5.3.2. Modified Sartorius Score (MSS) of HS
5.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
5.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
5.3.5. Pathophysiology of Hidradenitis Suppurativa
5.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)
5.4. Diagnosis of Hidradenitis Suppurativa (HS)
5.4.1. Differential Diagnoses
5.4.2. Biomarkers of Hidradenitis Suppurativa (HS)
5.4.3. Risk Factors and Complications
6. Epidemiology and Patient Population
6.2. Assumptions and Rationale: 7MM
6.3. Total Prevalent Patient Population of HS in the 7MM
6.4. Total Diagnosed Prevalent Patient Population of HS in the 7MM
6.5. Gender-Specific Prevalent Patient Population of HS in the 7MM
6.6. Age-Specific Prevalent Patient Population of HS in the 7MM
6.7. Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM
6.8. Treated Prevalent Cases of HS in the 7MM
7. Country-wise Epidemiology of HS in the 7MM
7.1.1. Total Diagnosed Prevalent cases of HS in the United States
7.1.2. Gender-Specific Prevalent cases of HS in the United States
7.1.3. Age-Specific Prevalent cases of HS in the United States
7.1.4. Stage-Specific Prevalent Cases of HS in the United States
7.1.5. Treated Prevalent Cases of HS in the United States
8. Current Treatment Practices
8.1. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa
8.2. North American Clinical Management Guidelines for HS
8.3. British Association of Dermatologists guidelines for the management of Hidradenitis Suppurativa (Acne Inversa) 2018
9. Patient Journey of Hidradenitis Suppurativa (HS)
11. Key Endpoints in Hidradenitis Suppurativa (HS) Clinical Trials
13.1. Key Cross of Emerging Therapies
13.3. Cosentyx (Secukinumab): Novartis Pharmaceuticals
13.4. INCB054707: Incyte Corporation
13.5. CJM112: Novartis Pharmaceuticals
13.6. Bimekizumab: UCB Biopharma S.P.R.L.
13.7. Bermekimab (MABp1): Janssen Pharmaceutical
13.8. CFZ533 (Iscalimab) and LYS006: Novartis
13.9. Apremilast: Celgene
13.10. Avacopan: ChemoCentryx
13.11. PF-06650833, PF-06700841, and PF-06826647: Pfizer
13.12. Risankizumab: AbbVie
13.13. Guselkumab: Janssen Pharmaceutical
14. Attribute Analysis of Hidradenitis Suppurativa (HS) Therapies
15. Hidradenitis Suppurativa (HS): 7 Major Market Analysis
15.2. Market Size of Hidradenitis Suppurativa in 7MM
15.3. Market Size by therapies of Hidradenitis Suppurativa in 7MM
19. Market Access and Reimbursement Scenario of Hidradenitis Suppurativa (HS) Therapies
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 09/23/2020 08:38 AM/DISC: 09/23/2020 08:38 AM
Copyright Business Wire 2020.